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Introduction 
Atherosclerotic disease is a chronic disorder 
developing insidiously throughout the life and 
usually progressing to an advanced stage by the time 
symptoms occur. In order to realize cardiovascular 
(CV) prevention, the detection of asymptomatic but 
diseased patients is crucial for an early intervention, 
since in these subjects there are opportunities to alter 
the progression of disease and the outcome (1).  
 
However, the simply analysis of risk factors don’t 
permits to identify always these subjects since it 
doesn’t informs about the effect that risk factors (RF) 
had already provoked and may more provoke on the 
individual vasculature. Besides, the risk factors 
known predict can explain only the 90 percent of 
cardiovascular disease (CVD) and traditional 
algorithms for prediction of CV risk failed to predict 
a proportion of cardiovascular events (CVE), 
realizing a “risk factors prediction gap” (2). It may be 
explained by several reasons: the epidemiology-
derived models, based on the prediction of long-term 
risk, may not accurately predict short-term events, 
they don’t take into consideration emerging and 
novel risk factors; risk algorithms don’t identify, 
among patients with neither a previous history of 
CVD nor an high risk for atherosclerotic disease, 
those who will develop acute myocardial infarction 
and/or sudden coronary death as first CVD 
manifestation, and this may be due to the fact that the 
factors responsible of plaque formation and growth 
are not necessarily the same responsible of its 
instability and rupture, being the latter related to 
inflammation, thrombosis and plaque morphology 
(3).   
 
So, a possible approach to evaluate the individual 
global cardiovascular risk with more accurateness is 
to identify risk factors combination that more easily 
produces vascular damage, or alternatively, to 
evaluate directly the arterial wall and its damage 
degree. The former approach is performed by the 
evaluation of metabolic syndrome, the latter by the 
non-invasive study of pre-ATS markers. 
 
Metabolic Syndrome 
The metabolic syndrome is a complex of correlated 
risk factors for CVD and type 2 diabetes mellitus 
occurrence. Risk factors include high blood pressure, 
cholesterol, triglycerides levels and fasting glucose, 
low high-density lipoprotein levels and abdominal 
obesity. The presence of at least three of these factors 
is diagnostic of Met-S (16) (see Table 1). It doesn’t 
represent the individual absolute risk for CVD, since 
it doesn’t comprise other elements that are important 
in the global risk determination, but it is the sign that 
metabolism abnormalities capable of maintain and 
enhance themselves are established. Indeed, these 
metabolic alterations occur together more often that 
would be expected and the risk associated to their 
clustering is greater than the sum of the risk 
associated with each factor alone. Besides, the risk 
increases with number of MetS components (5).  
 
All the factors characterizing the MetS are 
responsible for the endothelial dysfunction and for 
the progression of atherosclerotic lesions. Therefore, 
it doesn’t surprise that the diagnosis of MetS is 
related to the IMT and to the velocity at which it 
increases over time (6, 7). The components of MetS 
interact synergistically to affect vascular thickness 
and promote the development of subclinical 
atherosclerosis and overt carotid atherosclerosis (8); 
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occurrence of MetS is associated with the 
acceleration of carotid IMT increase (11). Indeed, it 
has been observed that the incidence of CVE was 
higher in subjects affected by MetS, both in those 
with and in those without pre-ATS, and that the 
coexistence of MetS and pre-ATS enhanced the risk 
of CVE. Among the different subgroup of subjects, 
the greater incidence of events was recorded in those 
affected by both pre-ATS and MetS, rather than in 
those affected by only one or neither of these two 
conditions. Therefore, the presence of pre-ATS 
enhances the power of MetS to favor cerebro- and 
cardiovascular events occurrence in twenty years 
follow-up (10).
 
Table 1. Criteria for clinical diagnosis of the metabolic syndrome according to the 2009 Joint Scientific Statement 
on MetS (4). 
 
 
HDL-C indicates high density cholesterol;  
*It is recommended that the IDF cut points be used for non-Europeans and either the IDF or AHA/NHLBI cut points 
used for people of European origin until more data are available. 
†The most commonly used drugs for elevated triglycerides and reduced HDL-C are fibrates and nicotinic acid. A 
patient taking 1 of these drugs can be presumed to have high triglycerides and low HDL-C. High-dose ω-3 fatty 
acids presumes high triglycerides. 
‡Most patients with type 2 diabetes mellitus will have the metabolic syndrome by the proposed criteria. 
   
Several studies have confirmed the association 
between MetS and CVD. MetS is correlated with 2-
fold increased risk of developing CVD over the next 
5 or 10 years, 2- to 4-fold increased risk of stroke, 3- 
to 4- fold increased risk of MI, and 2-fold increased 
risk of dying from such an event (11), regardless of a 
previous history of CVD (12) or the diagnostic 
criteria used (16). A study conducted in elderly failed 
to demonstrate a relationship between MetS and CV 
risk (14). Moreover, the prospective studies that 
investigated the relationship between MetS and CVE, 
were carried out for long follow-up period, until to 20 
years (15). It suggests that MetS prognostic power is 
better on long term follow-up, while on short term (5-
10 years) the traditional risk scores are more accurate 
(16); it may be explained by the role that the MetS 
have in the initiation and progression of 
atherosclerotic process, rather than in the plaque 
instability.  
 
Preclinical atherosclerosis 
Atherosclerotic process develops gradually over the 
year. First lesions are detectable in children and 
adolescents: they are fatty streaks that alter arterial 
tunicae and layers leading to a structural 
transformation of arterial wall without giving clinical 
signs; over time, they turn into atherosclerotic 
plaques that determine luminal restriction and 
symptoms appearance; they are vulnerable to 
complications related to plaque instability, that 
manifests as acute events (see Figure 1). The 
endothelium dysfunction have a crucial role in this 
process, since it represents both the final pathway 
whereby the CV risk factors provokes atherosclerotic 
lesions, and the factor determining the plaque 
vulnerability and the complications arising.  
During the early stage of this process, the anatomical 
but not functional alterations determine the absence 
of symptoms, although structural damage, even if 
minimal, is already present. This stage is named 
“preclinical atherosclerosis” (pre-ATS) and it is the 
sign that “something is beginning to change” in the 
vascular wall; but it is potentially susceptible to 
correction, thus, its detection advises that it would be 
useful to intervene. Preclinical lesions don’t occur 
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after the same time interval or with the exposure to 
the same number of CV risk factors in all patients 
(20). Indeed, in different subjects the vascular 
response to the same pathogen factor is various. This 
variability is probably due to genetic susceptibility, 
enhancement effect of the combination of risk 
factors, time and intensity of exposition to the same 
risk factors, interaction with environmental factors. 
 
 
Figure1. The natural history of atherosclerotic disease. From Stary HC et al. Circulaton1995; 92:1355-74 
To comprise the basis of pre-ATS assessment, we 
also must remember that the atherosclerosis is a 
systemic and multidistrict disease that begins at the 
same time but progresses with different velocity in 
the various districts affected. The different 
hemodynamic characteristics and the different 
responses to RF explain why some districts are 
involved before others or why their involvement is 
associated with different RF. Population studies 
demonstrate that the severity of atherosclerosis in one 
arterial territory is related to the involvement of the 
other districts (17). So, the identification of 
atherosclerotic damage in different artery, indirectly 
informs us of coronary damage. Among the different 
districts, the carotid arteries are the first involved, 
and the more easily assessed. These characteristics 
make them an optimal target for screening 
investigations.   
 
Preclinical atherosclerosis assessment. 
The understanding of role of the vascular 
endothelium in the atherosclerotic disease and the 
identification of subsequent stages of arterial wall 
damage has led to the development of invasive and 
non-invasive techniques to anatomical or functional 
assessment of pre-ATS.   
 
The carotid artery scanning through ultrasonography 
to evaluate intima-media thickness (IMT) identifies 
pre-ATS carotid involvement (but it may detect also 
carotid plaques that are sign of advanced 
atherosclerosis). The ankle-brachial index (ABI) 
evaluates the ileo-femoral-popliteal axis involvement. 
The measurement of the coronary calcium score by 
coronary computed tomography (CT) assesses the 
atherosclerotic burden in coronary artery. These 
techniques are the most widespread and an amount of 
data confirmed their predictive value for 
cardiovascular events and their utility in CV risk 
stratification. So, they appear among the imaging 
methods recommended by the last ESC guidelines of 
CVD prevention for risk assessment in asymptomatic 
adults at moderate risk (1).  
 
However, other techniques allow evaluating pre-
ATS, but they are less used since data about their 
predictive value are inconclusive, or their use is 
limited by invasiveness or availability, so they are 
nowadays research tools or investigation suitable for 
specific purposes. They include methods that assess 
endothelial dysfunction, vascular stiffness and 
techniques that visualize directly arterial wall.  
 
Among the techniques which evaluate the endothelial 
dysfunction, the most wide used is the brachial flow-
mediated dilatation (FMD), that assesses the 
vasomotor capacity of a large artery such as the 
brachial one; endothelial dysfunction may also be 
detected by venous occlusion pletismography and 
peripheral arterial tonometry, that are more 
influenced by small arteries and microcirculation 
function, or may be assessed by dosage of levels of 
circulating marker such as cellular adhesion 
molecules, von Willebrand factor, oxidized low 
density lipoproteins (LDL) and endothelial progenitor 
cells. 
 
The arterial stiffness, which is related also but not 
only to atherosclerotic process, can be evaluated by 
the pulse wave velocity (PWV) and by 
photophlethysmographic assessment of pulse wave 
reflection in finger digital arteries (19). 
 
The direct visualization of artery wall may be 
obtained through multislice CT coronary angiography 
that gives imagines of the coronary district; or 
Preclinical atherosclerosis → Clinical Manifestations→ Complications 
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through the magnetic resonance (RM) imaging of 
coronary wall, that is capable of identify positive 
remodeling in patient with subclinical 
atherosclerosis. Also the ophthalmoscopy allows the 
direct visualization of artery atherosclerosis but in 
retinal district; the wall-lumen ratio of small arteries 
can be measured invasively through subcutaneous 
gluteal biopsy (1). 
 
All these methods are related to coronary 
atherosclerosis but the role in CV risk assessment is 
not established for all these.  
In this review we limited the discussion to the 
technique that for easiness of execution or wide 
availability are suitable for large-scale CV risk 
prediction.  
 
Intima media thickness and carotid ultrasound 
Carotid artery IMT is the distance between the 
media-adventitia and the intima-media interfaces 
measured in a longitudinal scansion through B-mode 
ultrasonography. Its value correlates with anatomical 
layers thickness (see Figure 2).
 
 
Intima-media thickness varies with age gender and 
ethnicity and with the segment considered: it increase 
with age and is thicker in man than in women and in 
carotid bulb (CB) than in the other segments. 
Differences in measurement are registered also 
between ultrasound equipment used. All these factors 
make difficult to identify normal values, besides, 
cardiovascular risk gradually increases with rising 
IMT. However, a threshold value >0.9 mm is 
considered abnormal and it is a sign of early 
atherosclerosis (19).  
 
Plaque, instead, is sign of later stages of 
atherosclerosis: is defined as a focal structure of the 
inner vessel wall that encroaches into the arterial 
lumen at least ≥0.5 mm (or >50%) of the surrounding 
IMT, or any IMT measurement ≥1.5 mm.  
 
IMT depends not only on early atherosclerosis but 
also on smooth muscle hypertrophy or hyperplasia, 
related to genetic factors, hypertension, and age-
related sclerosis (1). Among risk factors, it correlates 
with traditional (hypertension, dyslipidemia, type 2 
diabetes mellitus, smoking) and non traditional 
(homocysteine, inflammation’s markers as C-reactive 
protein and fibrinogen, uric acid, type 1 diabetes or 
gestational diabetes) risk factors exposure (20).  
 
Different segment of carotid artery seems to be 
influenced by different factors and related to different 
outcomes. Diastolic blood pressure and fasting 
glucose relate better to the common carotid artery 
(CCA); plaques are more often located in CB or in 
internal carotid artery (ICA) than in CCA, probably 
because the first two tracts are submitted to low shear 
stress and to marked oscillations in the direction of 
wall shear stress, conditions that favors the plaque 
formation (19).  
 
It predicts the occurrence of myocardial and 
cerebrovascular events independently of CV risk 
factors (21). Increased IMT is related to rates of 
coronary heart disease (CHD), stroke, myocardial 
infarction and cardiovascular mortality. A recent 
meta-analysis calculated that every 0.1 mm rise in the 
IMT values increases the rate of myocardial 
infarction of 10–15% and the rate of stroke of 13–
18% (22). This correlation has been observed in 
several categories of asymptomatic subjects with CV 
risk factors , such as women in post-menopausal 
period (23), subjects with low HDL-cholesterol levels 
(24), metabolic syndrome (25) or with a cluster of 
CRF including age > 45 years and family history of 
cardiovascular disease (26) but also in young subjects 
(27) and in subjects without risk factors; in subject 
with and without previous vascular disease. A thicker 
IMT is also a negative prognostic factor after 
percutaneous coronary intervention (PCI) (28) and 
after coronary artery bypass graft (CABG) (29).  
 
The predictive value holds true for both carotid 
bifurcation and common carotid artery, although the 
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first reflects primarily atherosclerosis and the second 
vascular hypertrophy. From separated analysis of 
cardio and cerebrovascular events rates emerges that 
ICA IMT is stronger associated with incident 
myocardial infarction, while CCA IMT is stronger 
associated with stoke incidence (30). Besides, 
predictive value seems to be greater in women than in 
men. The relative risk for events is slightly lower 
after adjustment for the presence of traditional risk 
factors, but it remains elevated at higher IMT value. 
The risk for cardio and cerebro-vascular events is non 
linearly related to IMT, since it increases more 
rapidly at lower than at higher IMT value (1, 31).   
 
Even though, the evidence to support the carotid IMT 
measurement to help risk stratification is limited. Has 
been calculated that presence of a plaque and 
increased carotid IMT add little to each other for 
predicting CV events in top of traditional risk score, 
such as Framingham or SCORE (32), although it 
permits reclassifying patients in another risk category 
in ARIC study, and stratify with more accurateness 
CV risk (the ARIC study has published a calculator 
incorporating IMT and plaque assessment to 
Framingham risk score) (33). Thus it is not 
recommended as screening investigation for overall 
asymptomatic patients, but as tool for further risk 
stratification and assess end-organ damage in patients 
at intermediate risk (34). A recent systematic review 
concluded that the added predictive value may be 
primarily found in asymptomatic individuals at 
intermediate CV risk. Thus, in these subjects, it may 
help to make decisions about the appropriateness of 
medical treatment for primary prevention. 
 
Also plaque characteristics are predictive for CV 
events: echo lucent stenotic plaques are related to a 
much higher risk of cerebrovascular events than other 
plaque types (1).    
 
However, increased CIMT is evident when 
atherosclerotic damage is already present, thus is a 
later predictor of coronary disease compared to other 
pre-ATS marker such as endothelial dysfunction that 
become evident earlier.  
 
Ankle-brachial index 
The ankle-brachial index (ABI) is the ratio between 
the blood pressure in ankle and that in brachial artery. 
It is performed through automated device or with a 
continuous wave Doppler unit and a 
sphygmomanometer (see Figure 3). Physiologic ratio 
is > or = 1. An ABI < 0.9 is a marker of peripheral 
artery disease (PAD) since indicates ≥50% stenosis 
between the aorta and the distal leg arteries, and then 
advanced atherosclerosis, although yet asymptomatic 
(34).  
 
The ABI value is related with all CV risk factors, 
particularly with smoke and diabetes mellitus and 
age.
 
 
 
A reduced ABI is related to multifocal ATS: it is 
associated with presence and extension of coronary 
atherosclerosis, and with IMT values in femoral and 
carotid districts (35).  
 
It identifies a subgroup of subject, also among 
asymptomatic for PAD, at higher risk coronary heart 
disease: it is predictive of development of angina, 
myocardial infarction, congestive heart failure, 
CABG surgery, stroke, or carotid surgery (36). It 
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confers twice 10-years CV mortality and major 
coronary event (non fatal MI, unstable angina, 
myocardial revascularization) risk compared with the 
overall rate in each Framingham category. It is 
associated with an incidence of CV morbid and fatal 
events of about 20% in 10 years (37). In PAD 
subgroup of CAPRIE study, for every 0.1 reduction 
in ABI a 10.2% increase of risk of dying or CV 
events occurrence was registered (38).  
 
The prevalence of a reduced ABI is about of 25-50% 
in subjects selected for history of diabetes, smoke 
habitus or age>70 years (39); for this reason TASC II 
Consensus Document recommended its assessment in 
these population, in subject at intermediate risk 
according Framingham score and in subjects 
complaining symptoms of claudicatio (40).  
 
 
 
Flow-mediated vasodilatation 
Endothelial function may be explored evaluating 
vasomotor response to a stimulus that determines the 
release of vasoactive substances by endothelium and 
requires its integrity. It may be realized, in a 
noninvasive manner, inducing a transitory ischemia 
on brachial district through the inflation of a 
sphygmomanometer cuff on proximal or mid-
forearm, and assessing the artery diameter by 
ultrasound. The ischemia provokes the reduction of 
peripheral resistances mediated by adenosine and, 
then, after the cuff deflation, a reactive hyperemia; 
the shear stress on endothelium, in turn, leads to NO 
release and brachial artery dilatation (41). The FMD 
is calculated as the ratio of the difference between the 
maximum diameter post-occlusion and baseline 
diameter to the baseline diameter, and is expressed as 
a percentage (see Figure 4). This variability in 
vasomotion represents a barometer of the other 
endothelium key functions (42). 
 
                                                    A B 
Figure 4.  Ultrasound image of the brachial artery at (A) baseline and (B) 1 min after hyperemic stimulus. 
Corretti M C et al. J Am Coll Cardiol. 2002; 39(2):257-265 (43). 
 
FMV has been shown to be affected by CV 
traditional risk factors, such as age, elevated 
cholesterol levels, diabetes mellitus, hypertension, 
active and passive smoking, and less traditional, such 
as microalbuminuria, obesity, inflammation (42). The 
FMD impairment correlates with number of risk 
factors present and with other pre-ATS markers such 
as IMT (44). Has been hypothesized that, respect to 
IMT, endothelial dysfunction it may be an earlier 
predictor of CAD, while the morphological changes 
of artery well are better correlated with the extension 
and severity of coronary artery disease (46). In the 
other hand, morphological alterations are predictive 
of FMD (44), and it may depends on the common 
pathogenesis, but also on the impairment of the 
dilatation capacity of artery wall consequent to the 
structural damage induced by the atherosclerosis 
(such as the loss of the elastic component of 
extracellular matrix and the reduced smooth cell 
responsiveness to NO) (46). Thus, FMD evaluation 
may be more useful in subject at low-moderate risk 
and affected by early atherosclerosis.   
 
The FMD is related to coronary endothelial function 
(47) and it has independent prognostic role in 
asymptomatic subjects, being predictive of CVE, also 
after statistical correction for CV RF (48) but adds 
little to the predictive model involving traditional risk 
factors (49). Since some studies conducted on elderly 
cohort have reported no predictive value over 
traditional RF, has been suggested that it may be less 
predictive in older subjects due to the limited arterial 
distensibility (51). It shows prognostic value in 
patient with established CVD or at moderate to high 
risk for CVD occurrence, since its impairment is 
associated with CVD such as CV death, myocardial 
infarction, stroke, congestive heart failure, 
intermittent claudication, percutaneous intervention, 
cardiac bypass graft surgery and restenosis (49).  
 
Some authors rise the question that the different 
measurement protocols, with cuff placement in 
proximal or distal limb, may result in more or less 
NO-dependents vessel responses (distal limb method 
seems to be more NO dependent); however, this 
don’t seems to reduce the predictive value of this 
technique; therefore, this suggests that the predictive 
value of FMD doesn’t depend solely on the 
endothelial NO metabolism (50).  
 
Coronary Calcium Score 
The coronary calcium content is the solely 
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consequence of atherosclerotic disease, with 
exception of chronic renal failure that determines 
artery wall calcification. Through multidetector CT it 
is possible to quantify calcified lesion in term of 
Agatston score (52). This score  is related to the 
atherosclerotic burden, but it has some limits: 
although a zero score generally predicts an excellent 
prognosis, it cannot rule out coronary stenosis, 
especially in younger patients presenting an acute 
coronary syndrome, either unstable angina or non 
ST-elevation myocardial infarction (1) since 
atherosclerosis not always leads to artery wall 
calcification. Besides, coronary calcifications don’t 
inform about the plaque stability (53) or the luminal 
narrowing degree.  
 
However calcium score shows a prognostic value, 
since higher score correlate with increased risk of 
myocardial infarction independent of classical RF 
(54). Has been calculated that every one standard-
deviation increase of log-transformed CAC score, the 
risk of CVD is 2.1-fold higher. Respect to IMT, it has 
similar predictive value, since hazards ratios for total 
CVD and coronary heart disease are been recorded 
with the two techniques, although IMT is more 
stronger related to cerebrovascular disease than CAC 
score, while CAC score is a better predictor of 
incident CVD (55). 
 
Computed tomography coronary angiography 
After injection of contrast agents, CT permits 
coronary artery lumen visualization and then CAD 
detecting (see Figure 5). It requires patients selection 
(adequate breath holding capability, sinus rhythm, 
low Agatston score, adequate weight are essential) 
and has some limits (visualization of the arteries 
treated with stents, of the native arteries post bypass 
graft and of the artery with high grade calcification 
segments) but shows high sensitivities (95–99%) and 
specificities (64–83%) for the detection of at least 
one stenosis at coronary angiography (56). It also 
demonstrates high negative predictive values (97–
99%) and patients in whom CTA rule out coronary 
stenosis have an excellent prognosis (57). Although it 
allows to individuate subclinical atherosclerosis and 
to characterize the plaque nature, there are no data to 
recommend it as a screening investigation in 
asymptomatic individuals with prevention purpose 
(1). Instead, CTA is recommended in the setting of 
the non-invasive diagnosis of stable coronary artery 
disease, where it may be useful both in subjects at the 
lower range of intermediate pre-test probability for 
CAD disease and in those with a stress test result that 
contradicts clinical judgment (56).
 
 
Figure 5. On the left two 3D volume rendering images and on the right two 2D CT coronary angiography 
scanning. 
 
Pulse wave velocity   
The arterial stiffness is a consequence of structural 
alteration related to the atherosclerosis process and 
other causes of vascular damage, and it is 
consequence and cause of cardiovascular disease. 
The pulse wave velocity is measured recording 
arterial pulse wave in two different sites and 
calculating the propagation velocity by their retard of 
appearance and their distance (see Figure 6); it is 
expression of arterial stiffness. The carotid-femoral 
PWV is the gold standard measure to assess the aortic 
stiffness (58). The normal value is <10 m/s (59). The 
PWV increases in presence of CV risk factors such as 
hypertension, hypercholesterolemia, diabetes mellitus 
and renal dysfunction. It is an independent risk 
marker for cardiovascular mortality and 
cerebrovascular events, and has prognostic value 
equivalent to other marker of pre-ATS. Has been 
calculated that the PWV has additive value above and 
beyond the traditional risk factors score, and when it 
is evaluated, a proportion of subject at intermediate 
risk could be reclassified into a higher or lower risk 
category (60). 
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Figure 6. PWV is measured recording pulse wave in two different sites and calculating their distance and the 
retard wherewith it appears in distal site, if recorded simultaneously, or their retard respect to the QRS 
complex of ECG used as reference frame, if recorded on separated occasion. 
 
Conclusion. 
The CVD represent nowadays the first cause of 
mortality and disability in western country. But 
atherosclerosis disease is a gradually process that 
develops over decades, giving the time to carry out 
prevention and intervention strategy. Great attention 
should be made on the analysis of RF and on their 
correction, especially when they are clustered in a 
manner that enhances them. For this reason, it’s 
important to prevent the development of MetS 
abnormalities (for example with daily physical 
activity and Mediterranean diet) and to detect it early 
so as start pharmacological treatment of modifiable 
risk factors. Moreover, in order to address the 
therapeutic efforts to the subjects that can receive 
greater benefit, it is important to have tool to identify 
subjects affected but non symptomatic yet. For this 
purpose, non-invasive techniques capable of 
evaluating arterial wall and endothelial function 
should enter in routinely evaluation of cardiovascular 
risk. In particular, according to ESC guidelines (1), 
carotid ultrasonography, brachial-ankle index 
measurement and computed tomography for coronary 
calcium assessment should be taken in mind for 
further risk stratification of asymptomatic adults at 
moderate risk. The detection of subclinical lesions 
indicates the need of a more aggressive management 
of risk factors, possibly with the help of drug 
treatment.    
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